PHARPharming Group N.V.
Is the price fair?
Modest expectations priced in. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Priced for a decline (~−0% a year). The price demands less than its three-year revenue growth of 22% a year, expectations look modest.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What PHAR's price assumes
Today's price asks for −0.40% free cash flow growth a year; over the last three years Pharming Group N.V. delivered 37%, less than the record.
Price / sales · no trailing P/E on file: measured against sales instead
- Free cash flow yield
- 7.9%
Free cash flow yield · Biotechnology median 3.6%
- Growth the price implies
- −0.40%
Growth the price implies · The price pays for −0.40% free cash flow growth a year for a decade; the business has delivered +37% a year over the last three.
- Price / book
- 4.37
Price / book · as of 2026-Q1
Details›
- Price / bookas of 2026-Q1
- 4.37
- EV / EBITas of 2026-Q1
- 57.7
- EV / salesas of 2026-Q1
- 3.35
- Free cash flow, trailing twelve months
- $54M
- Market capitalisation
- $685M
- 3-year revenue growth
- +22%
- 3-year free cash flow growth
- +37%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.